Gastric retention
Also known as: Stomach, Gastric, Peptic, Belly
Methodology & AI Transparency ⓘ
Gastric retention Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Acid Reflux, GERD & Upper GI Health practice, Gastric retention (also termed Stomach or Gastric) (ICD-10 K31.89) is stratified through mucosal protective therapy [Gastric retention K31.89], pairing targeted symptom control with longitudinal Serum Vitamin B12 in Gastric retention (K31.89: & Magnesium (chronic) surveillance.
- 2 Real-world patient consensus: Mapped to Acid Reflux, GERD & Upper GI Health under ICD-10-CM K31.89 for Gastric retention clinical workups.
- 3 Typical cash cost range: Workup highlights for Gastric retention (K31.89): mucosal protective therapy [Gastric retention K31.89].
- 4 Top reported side effects / signs: Longitudinal Gastric retention monitoring tracks Hemoglobin & Serum in Gastric retention (K31.89: Ferritin) toward Ferritin > 50 ng/mL (no occult loss) (K31.89).
Ask our AI Specialists anything about Gastric retention
What Is Gastric retention?
Within Acid Reflux, GERD & Upper GI Health practice, Gastric retention (also termed Stomach or Gastric) (ICD-10 K31.89) is stratified through mucosal protective therapy [Gastric retention K31.89], pairing targeted symptom control with longitudinal Serum Vitamin B12 in Gastric retention (K31.89: & Magnesium (chronic) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Gastric retention (K31.89) center on impaired esophageal peristaltic in Gastric retention (K31.89: clearance). targeted gerd & stomach interventions aim to normalize Hemoglobin & Serum in Gastric retention (K31.89: Ferritin).
Common Symptoms & Clinical Signs
- • Presentation of Gastric retention (K31.89): chronic throat clearing, in Gastric retention (K31.89: hoarseness, nocturnal cough,)
- • Secondary Gastric retention clinical sign: nausea, belching, or in Gastric retention (K31.89: discomfort relieved or)
- • Symptom flares in Gastric retention correlating with Hemoglobin & Serum in Gastric retention (K31.89: Ferritin) deviation outside Ferritin > 50 ng/mL (no occult loss) (K31.89)
- • Functional gerd & stomach impact requiring mucosal protective therapy [Gastric retention K31.89] evaluation (K31.89)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Gastric retention Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K31.89 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Acid Reflux, GERD & Upper GI Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hemoglobin & Serum in Gastric retention (K31.89: Ferritin) | Ferritin > 50 ng/mL (no occult loss) (K31.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Gastric retention (K31.89: & Magnesium (chronic) | B12 > 450 pg/mL; Mg >= 2.0 mg/dL (K31.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: H. pylori Stool in Gastric retention (K31.89: Antigen or Urea) | Negative (K31.89) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Gastric retention
Treatment selection for Gastric retention depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Gastric retention)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Phase III Study to Evaluate real-world benefits and safety of Andecaliximab With: What a 432-Participant Study Found The addition of ADX to mFOLFOX6 did not improve OS in unselected patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2021-03-20 • Phase III Randomized Trial | N = 432 | 93/100 | PMID 33577358 ↗ |
| Can This Approach Help? Inside the Latest Research on Laparoscopic adjustable gastric banding with liraglutide in adults with obesity Our pilot data suggest no additional improvement in glycaemic control or BW with LAGB and liraglutide therapy. International journal of obesity (2005) • 2023-11-15 • Randomized Controlled Trial | N = 13 | 88/100 | PMID 37696925 ↗ |
| Can This Approach Help? Inside the Latest Research on Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Delayed gastric emptying appears to play little direct role in appetite suppression induced by liraglutide. Obesity (Silver Spring, Md.) • 2026-08-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 42392577 ↗ |
| Can This Approach Help? Inside the Latest Research on Body weight loss as a prognostic and predictive factor in previously treated In TAGS, early BWL was a strong negative prognostic factor for OS in patients with mGC/GEJC receiving third- or later-line treatment. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association • 2023-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37106214 ↗ |
| Can This Approach Help? Inside the Latest Research on A randomized, gold-standard blind, compared against a dummy pill (placebo) trial Liraglutide was significantly more effective than placebo in treating weight regain that occurs post-RYGB without increased SAE. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery • 2025-02-15 • Randomized Controlled Trial | N = 89 | 88/100 | PMID 39401933 ↗ |
Gastric retention Patient Community & “People Like Me” Threads
Filter Gastric retention community threads and patient logs by age, biological sex, dosage, and treatment duration.